Skip to content
Back to news
IndustryNovember 21, 2026

Novartis Shares Fall 3.3% After It Sets a 5% Yearly Growth Goal

Novartis Shares Fall 3.3% After It Sets a 5% Yearly Growth Goal: PharmoniQ news card

Novartis now expects its sales to grow about 5% a year through 2031. The Swiss drugmaker set out the new target around its Meet Novartis Management investor event in London this week. Its shares fell 3.3% on Nov. 19, Reuters reported.

What happened

Novartis expects sales to grow about 5% a year at constant currencies from 2026 through 2031, PharmExec reported. The company kept its goal of a core operating margin above 40% by 2029.

According to Reuters, the new goal sits at the bottom of the 5% to 6% yearly range Novartis set last year for 2025 to 2030. Analysts expect about 4.5% a year over the new period, Reuters said.

Novartis raised its peak sales forecasts for three medicines, Reuters reported:

  • Kesimpta: USD 8 billion, up from USD 6 billion.
  • Scemblix: USD 5 billion, up from USD 4 billion.
  • Leqvio: USD 5 billion, up from USD 4 billion.

Why it matters

Novartis is working through the loss of patent protection on older products. Reuters said Entresto sales are expected to drop by USD 4 billion this year. Kisqali and Cosentyx face cheaper rivals after 2030, it added.

Reuters said the 3.3% drop was set to be the stock's biggest one-day loss since Sept. 8, when the shares sank nearly 11%. That day, Novartis said del-desiran, a drug for the rare muscle disease DM1, missed the main goal of a late-stage study, BioPharma Dive reported.

Novartis got del-desiran in its USD 12 billion purchase of Avidity Biosciences. Even after the latest fall, the shares were still up 16% for the year, according to Reuters.

Daniel Bolanowski, a portfolio manager at Arctic Asset Management, said his worry is the period after the next five years, which the company has not fully addressed, according to Reuters. Urban Fritsche of Zürcher Kantonalbank called the outlook fair but a story Novartis must now prove.

What it means for people in the industry

Reports of the event did not mention job cuts, hiring or site changes. Chief executive Vas Narasimhan said deals and business development should add to growth at about the same level as in the past, according to Reuters. He also said most growth after 2031 should come from medicines developed in house, PharmExec reported.

Reuters said Novartis has 10 late-stage medicines it sees as having multibillion-dollar sales potential. Watch for their trial readouts and any deals that change the 2031 outlook.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.